Cargando…

Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study

Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF). HF and type 2 diabetes mellitus (T2DM) frequently coexist, with a prevalence of T2DM of 35%–40% in patients with HF. T2DM is the third co-morbidities in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armentaro, Giuseppe, D’Arrigo, Graziella, Miceli, Sofia, Cassano, Velia, Perticone, Maria, Maio, Raffaele, Marra, Alberto Maria, Arturi, Franco, Cittadini, Antonio, Tripepi, Giovanni, Sesti, Giorgio, Sciacqua, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174635/ https://www.ncbi.nlm.nih.gov/pubmed/35694400 http://dx.doi.org/10.3389/fphys.2022.897109

Ejemplares similares

Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
por: Armentaro, Giuseppe, et al.
Publicado: (2021)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
por: Cassano, Velia, et al.
Publicado: (2022)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022)

Ferritin modifies the relationship between inflammation and arterial stiffness in hypertensive patients with different glucose tolerance
por: Sciacqua, Angela, et al.
Publicado: (2020)

Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction
por: Cloro, Cosima, et al.
Publicado: (2022)

Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation
por: Armentaro, Giuseppe, et al.
Publicado: (2023)

Alkaline phosphatase affects renal function in never-treated hypertensive patients: effect modification by age
por: Sciacqua, Angela, et al.
Publicado: (2020)

Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients
por: Armentaro, Giuseppe, et al.
Publicado: (2022)

Association Between Sleep Apnea and Valvular Heart Diseases
por: Pelaia, Corrado, et al.
Publicado: (2021)

Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study
por: Pelaia, Corrado, et al.
Publicado: (2021)

Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance
por: Cassano, Velia, et al.
Publicado: (2020)

Oxidative Stress and Left Ventricular Performance in Patients with Different Glycometabolic Phenotypes
por: Cassano, Velia, et al.
Publicado: (2022)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Association between One-Hour Post-Load Plasma Glucose Levels and Vascular Stiffness in Essential Hypertension
por: Sciacqua, Angela, et al.
Publicado: (2012)

Immuno-Mediated Inflammation in Hypertensive Patients with 1-h Post-Load Hyperglycemia
por: Perticone, Maria, et al.
Publicado: (2022)

Different Patterns of Left Ventricular Hypertrophy in Metabolically Healthy and Insulin-Resistant Obese Subjects
por: Sciacqua, Angela, et al.
Publicado: (2020)

Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes
por: Ministrini, Stefano, et al.
Publicado: (2021)

Association between Noninvasive Fibrosis Markers and Chronic Kidney Disease among Adults with Nonalcoholic Fatty Liver Disease
por: Sesti, Giorgio, et al.
Publicado: (2014)

Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects
por: Succurro, Elena, et al.
Publicado: (2021)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Endothelial dysfunction and C‐reactive protein predict the incidence of heart failure in hypertensive patients
por: Maio, Raffaele, et al.
Publicado: (2020)

New potential biomarkers for early chronic kidney disease diagnosis in patients with different glucose tolerance status
por: Cassano, Velia, et al.
Publicado: (2023)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Serum Uric Acid and 1-h Postload Glucose in Essential Hypertension
por: Perticone, Francesco, et al.
Publicado: (2012)

One-Hour Postload Plasma Glucose Levels and Left Ventricular Mass in Hypertensive Patients
por: Sciacqua, Angela, et al.
Publicado: (2011)

Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients
por: Perticone, Maria, et al.
Publicado: (2016)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
por: Ai, Jiao, et al.
Publicado: (2021)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
por: De Vecchis, Renato, et al.
Publicado: (2020)

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
por: Gallo, Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ri6benhj0ccs5jk35v5n5jmk5